Cryoport Inc. has been selected by Celularity, a leading allogenic cell therapy company, to utilise its complete range of temperature-controlled solutions.
The agreement will give Celularity access to Cryoport’s full suite of temperature-controlled logistics solutions, including the Cryoport Express® shippers, the Cryoportal® Logistics Management Platform, Smartpak II™ Condition Monitoring System and logistics support.
“We are proud to support Celularity’s clinical programmes for the development of transformative allogeneic cell therapies,” said Jerrell Shelton, CEO of Cryoport.
“Cryoport’s end-to-end, industry-leading, temperature-controlled logistics solutions protect the biologic commodities that underpin these potentially ground-breaking therapies and play a vital role in their development,” Shelton continued.
“Celularity’s IMPACT™ platform seamlessly integrates bio sourcing through advanced cell manufacturing and productization of allogenic placental-derived cell therapeutics,” said John R. Haines, Chief Administrative Officer of Celularity.
“Industry-leading supply chain management tools are critical to our ability to deliver transformative, on-demand, off the shelf therapeutic options to patients in the US and worldwide. We look forward to partnering with Cryoport for cell therapy product logistics management,” Haines concluded.